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p21A zinc-ﬁnger protein which regulates apoptosis and cell cycle arrest 1 (Zac1) is a novel seven-zinc-ﬁnger
protein that can bind a speciﬁc GC-rich DNA element and has intrinsic transactivation activity; therefore, its
role as a transcription factor has been proposed. Zac1 not only promotes cell cycle arrest and apoptosis but
also acts as a transcriptional cofactor for nuclear receptors and p53. In this study, we examined the functional
roles of mouse Zac1 (mZac1) in HeLa cells treated with 12-O-tetradecanoylphorbol-13-acetate (PMA), a
potent Activator protein 1 (AP-1) activator. At ﬁrst, we found that mZac1 prolonged and enhanced PMA-
induced AP-1 activity in both HeLa and HeLa/p53 shRNA cells. We further identiﬁed physical and functional
interactions between mZac1 and AP-1 proteins (either c-Jun, c-Fos or both). Finally, we showed that Zac1
might function as a selective coactivator of AP-1, demonstrated by AP-1-dependent transcriptional activation
of collagenase, c-Fos and p21WAF1/Cip1 promoter activities. Identiﬁcation of AP-1 as a speciﬁc target for Zac1-
mediated transcriptional events not only establishes a direct link between these two pivotal regulatory
proteins but also raises the possibility that Zac1 contributes to certain AP-1-dependent biological effects.91; fax: +886 2 87927181.
ang).
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Activator protein 1 (AP-1) transcription factors belong to a group
of dimeric complexes composed of members in the Jun, Fos, activating
transcription factor (ATF) and musculoaponeurotic ﬁbrosarcoma
protein families. These transcription factors are known as basic
leucine-zipper proteins, as the subunits dimerize via a leucine-zipper
motif and contact the DNA-binding sequence via adjacent basic
domains. [1–3]. AP-1 recognizes the TPA-responsive element (TRE),
and its DNA-binding activity is strongly enhanced by the tumor
promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA; PMA). In
addition, it is known that AP-1 DNA-binding activity is rapidly
induced by other factors, including oncoproteins, cytokines and
growth factors, all of which are implicated in cell proliferation,
differentiation, survival and transformation [4]. Several AP-1 proteins,
such as c-Fos, FosB and c-Jun, can transform cells efﬁciently in cell
culture, and all of these proteins have potent transactivation domains,
which were identiﬁed by their induction of target-gene transcription.
In contrast, AP-1 proteins that lack potent transactivation domains
have either weak transforming activity (for example, Fra-1 and Fra-2)
or no transforming activity (for example, JunB and JunD). Not only dosome Jun and Fos proteins lack transforming activity, but they can also
suppress tumorigenesis. AP-1 activity regulation is complicated and
occurs at various levels, including dimer composition and transcrip-
tional and post-translational events as well as ancillary protein
interactions [5,6].
Mouse and human Zac1 (mZac1 and hZac1, or pleomorphic
adenoma gene-like 1, PLAGL1) were identiﬁed in associationwith p53
in a functional screening system by their common ability to induce the
expression of the type 1 pituitary adenylate cyclase-activating
polypeptide receptor (PACAP-1-R) gene [7,8]. Activation of PLAG1 is
the most frequent gain-of-function mutation found in salivary gland
pleomorphic adenomas [9]. PLAG1 belongs to the highly conserved
PLAG superfamily, carrying seven N-terminal copies of a C2H2-type
zinc-ﬁnger motif and comprising two other members, PLAGL1 and
PLAGL2 [10]. Zac1 anti-proliferative activity is characterized by the
induction of extensive apoptosis and G1 cell cycle arrest [11].
Recently, Zac1 was demonstrated to be a sequence-speciﬁc DNA-
binding protein, indicating that Zac1 may play a role as a transcription
factor [11–15]. In addition, mZac1 has been reported to serve as a
transcriptional coactivator or a repressor for nuclear receptor activity
[16–21]. Interestingly, although mZac1 is a p53 transcriptional
coactivator, it has been shown to act as a corepressor for the human
papillomavirus (HPV) oncoprotein E6 by inhibiting p53-dependent
transcriptional activation of the p21WAF1/Cip1 (later referred to as p21)
gene. The mechanism for the aforementioned mZac1 transcription
cofactor activity might involve its ability to bind directly to nuclear
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and HPV E6. Apparently, the functional role of mZac1 as either a
coactivator, repressor or corepressor depends on the cell line used in
the transient transfection experiment, suggesting that cell-type-
speciﬁc proteins play a signiﬁcant role in determining the biological
process that Zac1 is involved in [21]. Undoubtedly, there are
unexplored factors able to recruit Zac1 to participate in additional
important functions.
PACAP-1-R expression could be induced by mZac1 (or hZac1) and
p53 via mechanisms that remain unclear. In light of PACAP's
neurotrophic and neuroprotective functions, transactivation of the
PACAP-1-R gene by mZac1 and p53 is intriguing and suggests a subtle
balance between death-promoting and protective mechanisms.
PACAP has been shown to activate the AP-1 (c-Jun:c-Fos) transcrip-
tion factor in rat pancreatic carcinoma cells, and it might stimulate
proenkephalin gene transcription via AP-1- and CREB-dependent
mechanisms [22,23]. Interestingly, AP-1 is reportedly involved in
different aspects of cell homeostasis. The tumor promoter, PMA, a
well-known AP-1 stimulant, may affect cell growth by inducing
expression of a number of genes, including c-Fos and c-Myc [24]. AP-1
is not only essential for proliferation and differentiation in certain cell
types, but it may also be required for certain cells to initiate
programmed cell death [1,2,25]. Likewise, mZac1 could also have a
critical function in controlling cell viability and eliminating damaged
cells [8,21]. Therefore, it is important to explore the transactivation
mechanisms employed by Zac1 and whether AP-1 plays a role in this
regulatory process.
Beyond PACAP-1-R stimulation of AP-1 function, the relationship
between Zac1 and AP-1 is not well understood. In this study, we
examined the functional roles of mZac1 in PMA-treated cells. At ﬁrst,
we demonstrated that mZac1 can prolong and enhance PMA-induced
AP-1 activity in HeLa cells. Then, we identiﬁed the physical and
functional interactions between mZac1 and AP-1 (c-Jun, c-Fos).
Finally, we showed that mZac1 might function, at least in part, as a
selective coactivator of AP-1-dependent transcriptional activation,
such as in collagenase, c-Fos and p21 gene expression.
2. Materials and methods
2.1. Plasmids
Reporter genes coll(−73/+63)-LUC, c-Fos promoter-LUC, p21-
LUC, 7xAP1-LUC and GK1 (Gal4RE-LUC) were described previously
[26–29]. Various AP-1 proteins fused with the pCI vector were a gift
from D Chalbos, served as PCR templates for various AP-1-coding
regions and were then sub-cloned into the EcoRI and XhoI sites of the
pSG5.HA vector, which has promoters for in vitro and mammalian cell
expression with an N-terminal HA-tag [21]. Various c-Jun and c-Fos
coding regions were synthesized by PCR and sub-cloned into the EcoRI
and SalI sites in the pGAL4DBD vector (Clontech, CA, USA), a vector
GAL4-DBD fusion protein expressed using a constitutive SV40 early
promoter. pDCR-RasV12 and pSG5.HA.mZac1 expression vectorswere
used as described previously [20,21,30]. Full-length mZac1 was
synthesized via PCR and sub-cloned into the pcDNA3.1/myc-His A
vector EcoRI and XhoI sites.
Bacterial expression vectors for GST fused to mZac11–520, and
mZac11–704 were constructed by inserting the appropriate PCR
fragments into pGEX-4 T1 (GE HealthCare, WI, USA) at the EcoRI–
XhoI sites.
2.2. Cell culture and transient transfection assays
For functional assays, HeLa and HeLa/p53 shRNA cells were grown
in DMEM supplemented with 10% charcoal/dextran-treated fetal
bovine serum. HeLa cells that were infected with human papilloma-
virus expressing the E6 oncoprotein, which maintains endogenouswild-type p53 at a very low concentration, were used as a model
system for studying human cervical tumorigenesis [20,31]. Endoge-
nous p53 expression silencing in HeLa cells was described previously
[32]. The lentiviral constructs encoding the sihZac1 hairpin (pLKO.1-
PLAGL1: TRCN0000021238) for gene silencing (shZac1) were
obtained from the National RNAi Core Facility (Academia Sinica,
Taiwan, Republic of China). HeLa cells were transduced with
lentiviruses at MOI of approximately 3–10. After transduction, cells
weremaintained in puromycin-containingmedium. Changes in hZac1
expression were determined using qRT-PCR. Transient transfections
and luciferase assays were performed in 24-well culture dishes as
described previously [33]. Total DNA was adjusted to 1 μg by adding
the necessary amount of the respective empty vector. The transfected
cell extract luciferase activity is presented in relative light units (RLU)
and expressed as the mean and standard deviation from three
transfected cultures. As mZac1 has been shown to greatly affect the
expression of many control vectors in monitoring transfection
efﬁciency (for example, mZac1 has been shown to enhance β-gal
reporter gene expression approximately 6–8-fold) [23], internal
controls were not used. Instead, reproducibility of the observed
effects on luciferase activity was determined via multiple indepen-
dent transfection experiments.
2.3. Immunoblots
HeLa cells were transfected with either mZac1, Ras(V12), HA.(or
Gal4DBD) c-Jun or c-Fos proteins. The transfected cell extracts were
lysed in RIPA buffer (100 mMTris–HCl pH 8.0, 150 mMNaCl, 0.1% SDS,
and 1% Triton ×-100) at 4 °C, separated by SDS-PAGE and analyzed via
immunoblot, with antibodies against c-Jun, p-c-Jun, c-Fos, p21, p53,
α-tubulin, Gal4DBD, p-histone H3, (H-79, KM-1, K-25, C19, DO-1, B-7,
RK51C, Ser 10, Santa Cruz, Biotechnology, CA, USA), γH2A.X (EP854
(2)Y, Epitomics, CA, USA), and HA (3 F10; F. Hoffmann-La Roche AG,
Basel, Switzerland).
2.4. Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was extracted from growing cells using a total RNA
reagent kit (Bioman, Taiwan, ROC) according to the manufacturer's
instructions. One microgram of total RNA was subjected to reverse
transcription using MMLV reverse transcriptase for 60 min at 37 °C
(Epicentre Biotechnologies, USA). PCR was performed in the linear
range (30 cycles) with primers speciﬁc for hZac1, p21, c-Fos, and
GAPDH. The sequences of the primers for the ampliﬁcation of target
genes were as following: hZac1 top-strand, 5′-ttcctcaccctggagaag-3′;
hZac1 bottom-strand, 5′-tccttgcatcctgtgtgg-3′; p21 top-strand, 5′-
atgtcagaaccggctgg-3′; p21 bottom-strand, 5′-ttagggcttcctcttgg-3′; c-
Fos top-strand, 5′-gactacgaggcgtcatcctc-3′; c-Fos bottom-strand, 5′-
gctctggtctgcgatggggcc-3′; GAPDH top-strand, 5′-aacggatttggccg-
tattggg-3′; GAPDH bottom-strand, 5′-gggatgaccttgcccacagcc-3′. The
thermocycling conditions were as follows: one cycle at 95 °C for 5 min
followed by 30 cycles of 95 °C for 45 s, 55 °C for 30 s, and 72 °C for
40 s. Ampliﬁed products were subjected to 1.2% agarose gel
electrophoresis and visualized by staining with ethidium bromide.
2.5. Protein–protein interaction assays
For GST pull-down assays, 35S-labelled proteins were produced
with the TNT T7-coupled reticulocyte lysate system (Promega, WI,
USA), and GST fusion proteins were produced in Escherichia coli BL21.
Radioactively labeled proteins were translated in vitro, incubated with
immobilized GST fusion proteins, eluted and analyzed by gel
electrophoresis as previously described [33]. For the association of
myc.mZac1 protein with HA.c-Jun, COS7 cells were transfected with
these expression vectors. After transfection, cells were lysed in RIPA
buffer at 4 °C. Lysates were subjected to immunoprecipitation with
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coupled protein A/G (Santa Cruz Biotechnology) for 3 h. Immunopre-
cipitates were separated by SDS-PAGE and analyzed by immunoblots,
using antibody against myc (9E10, Invitrogen, CA, USA).
2.6. Construction of tet-inducible HeLa/TR/mZac1 cell lines
To generate stable and inducible HeLa/TR/mZac1and HeLa/TR/LacZ
cell lines, we made tetR-expressing HeLa cell lines using pLenti6/TR
virus infection (Invitrogen). The virally infected cells were treated
with blasticidin (10 μg/ml) for 2 weeks, and the blasticidin-resistant
cells were selected. Next, we generated Lentivirus by transfecting
pLenti4/V5/mZac1 and pLenti4/V5/LacZ with ViraPower Packaging
Mix into 293FT cells according to the manufacturer's instructions
(Invitrogen) and infected the HeLa/TR cell lines with either mZacl- or
LacZ-expressing lentivirus. The cells were selected using blastcidin
(10 μg/ml) and zeocin (150 μg/ml) for 2 weeks.
2.7. Fluorescence-activated cell sorting (FACS) analysis
This analysis was based on the measurement of DNA content of
nuclei labelled with propidium iodide. For cell cycle evaluation, cells
were treated as for the proliferation experiments, washed with ice-
cold PBS and incubated with propidium iodide (0.05 mg/ml in PBS,
0.1% Triton X-100, and 0.01% RNase) for 15 min at room temperature
in the dark. Cells then were subjected to FACS and analysis of the cell
cycle was evaluated using FACSCalibur ﬂow cytometry (Becton-
Dickinson Biosciences, NJ, USA). Data were analyzed using the Cell
Quest Pro software package (Becton-Dickinson Biosciences).
2.8. Statistical analysis
Comparisons between groups were determined by the indepen-
dent t-test (SPSS Advanced Statistics 17.0). A P value below 0.05 is
reported as signiﬁcantly different between groups.
3. Results
3.1. mZac1 is able to prolong and enhance PMA-stimulated AP1-reponsive
activity in HeLa and HeLa/p53 shRNA cells
We transiently transfected mZac1 into HeLa and HeLa/p53 shRNA
cells to investigate its effect on AP-1 activity in PMA-treated cells
(Fig. 1A and B, AP1-LUC was driven by the promoter-proximal region
of the collagenase gene,−73 to +63, containing a canonical AP-1 site,
and 7xAP1-LUC was driven by an artiﬁcial promoter containing 7-
copy canonical AP-1 sites). Previous studies demonstrated that mZac1
is a putative p53 coactivator [17,20]; hence, we used HeLa/p53 shRNA
cells to rule out the involvement of p53 in mZac1-induced AP-1
activation. The maximum effects from PMA on induction of collage-
nase and 7xAP1-LUC promoter activities were observed after
approximately 10 h in both HeLa and HeLa/p53 shRNA cells (Fig. 1A
and B, compare indicated time, open circles). Transient transfection
with mZac1 enhanced PMA-induced promoter activity, and the
aforementioned effects were p53-independent (Fig. 1A and B,
compare indicated time, closed squares). Considering the physical
interaction between mZac1 and HPV oncoproteins (E6 or E7) [34], we
examined the functional roles of mZac1 in another cervical carcinoma
cell line, C33A, which is not HPV-infected, to rule out the involvement
of HPV oncoproteins. mZac1 exhibited similar effects on PMA-induced
AP1-LUC and 7xAP1-LUC promoter activity in C33A cells (data not
shown).
As PMA might induce c-Fos protein expression and phosphoryla-
tion, we examined the change in phosphorylated c-Fos protein levels
to verify the effect of PMA when transiently transfected HeLa cells
were exposed to PMA at the time points indicated in Fig. 1C. Thephosphorylated c-Fos protein level was highest after the cells were
treated with PMA for 6 h, and then it decreased to an undetectable
level (Fig. 1C). Our data suggest that transient transfection of mZac1
into HeLa cells had no effect on the amount of phosphorylated c-Fos
with prolonged PMA treatment (Fig. 1C, right panel). Transiently
transfected mZac1 did increase the endogenous c-Fos proteins, and
even transfected mZac1 declined in HeLa cells (Fig. 1C, compare lanes
1 to 9 and 2 to 10). We further silenced endogenous hZac1 in HeLa
cells and observed the down-regulation of AP1 target genes, including
c-Fos, collagenase, and p21, via RT-PCR analysis at the indicated time
point (Fig. 1D).
3.2. mZac1 physically interacts with selective AP-1 family proteins
PMA-induced AP-1 activity in cells might be mediated via the PKC
pathway and the enhanced DNA-binding activity of AP-1 complexes
that modulate the expression of responsive genes. The results in Fig. 1
imply that mZac1 might work on the AP-1 system via the
aforementioned mechanism. Hence, we examined whether mZac1
physically interacted with AP-1 family proteins using GST pull-down
assays. Various in vitro synthesized Jun (c-Jun, JunB and JunD) and Fos
family proteins (c-Fos, Fra-1 and Fra-2) bound to two immobilized
GST-fused mZac1 fragments, composed of either amino acids 1–704
or 1–520, indicating a direct interaction between mZac1 and c-Jun, c-
Fos and Fra-1 (Fig. 2A,B). In addition, our co-immunoprecipitation
analysis not only showed a physical interaction between mZac1 and
phosphorylated c-Jun in COS7 cells but also suggested that PMA
treatment might enhance this physical interaction (Fig. 2C, compare
lanes 1 and 2, IP with phosphorylated-c-Jun).
3.3. mZac1 speciﬁcally enhances the functional effects of c-Jun, c-Fos or
c-Jun:c-Fos heterodimers on AP-1 dependent promoters
The results, including the enhancement of PMA-induced collage-
nase and 7xAP1-LUC promoter activities via exogenousmZac1 and the
physical interaction between mZac1 and either c-Jun or c-Fos (Figs. 1
and 2), suggested that mZac1 might act as a potential coactivator for
AP-1. To this end, transient transfection with either c-Jun, c-Fos or c-
Jun:c-Fos was used to test the effects in HeLa cells (Fig. 3). c-Jun and c-
Fos acted synergistically, with and without PMA, on both the
collagenase promoter and 7xAP1-LUC promoter activities (Fig. 3,
compare histograms 1–4, closed columns). c-Jun and c-Jun:c-Fos
heterodimers synergistically enhanced mZac1-induced promoter
activity at these two promoters (Fig. 3, compare histograms 1–4,
open columns). Enhancement was further signiﬁcantly stimulated by
PMA (Fig. 3, compare top and bottom panel, pb0.005). However, the
suppression of mZac1-enhanced promoter activity by co-transfected
c-Fos, in the absence or presence of PMA, was observed at the
collagenase promoter (Fig. 3A, compare histograms 1 and 3, open
columns) but not the 7xAP1-LUC reporter (Fig. 3B, compare histo-
grams 1 and 3, open columns). mZac1, c-Jun and c-Fos protein
expressions were examined by western blot analysis (Fig. 3C).
The c-Jun serine residues at positions 63 and 73 are known as the
primary PMA-induced phosphorylation sites in several cell lines [35].
Next, we examined whether these c-Jun serine residues at positions
63 and 73 were involved in the mZac1-induced AP1-dependent
promoter activity enhancement. In both HeLa and HeLa/p53 shRNA
cells, the transactivation activity of c-Jun with double mutations from
serine to alanine at residues 63 and 73 was undetectable either alone
or with c-Fos, with and without PMA, at the 7xAP1-LUC promoter
(Fig. 4, compare histograms 1–6, open columns). Further, this c-Jun
mutant did not act synergistically with c-Fos and/or mZac1 on this
promoter activity (Fig. 4, compare histograms 1–6, closed columns).
Enhancement by c-Jun, c-Fos and mZac1 in HeLa/p53 shRNA cells was
weaker than in HeLa cells, suggesting that endogenous p53 is required
for AP-1 activation.
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Fig. 1. Transiently transfected mZac1 increased collagenase promoter activation induced by PMA-treated HeLa and HeLa/p53 shRNA cells. HeLa and HeLa/p53 shRNA cells were co-
transfected with the 0.5 μg of either Coll73-LUC (A) or 7xAP1-LUC reporter genes (B) and, where indicated, 0.5 μg of either empty vector (open) or mZac1 (closed), and the cells were
treated with PMA (162 nM) for the indicated times (hour). Luciferase activities in the transfected cell extracts were determined. RLU, relative light units. These data (A and B) are the
average of three experiments (mean±S.D.; n=3). (C) HeLa cells were transiently transfected with 1 μg of either pSG5.HA vector (left panel) or pSG5.HA.mZac1 (right panel), and
the cells were treated with PMA (162 nM) for the indicated time (hours). The cell extracts were subjected to Western blot analysis using either anti-HA, anti-c-Fos or control α-
actinin (ACTN) antibodies. (D) Messenger RNA levels of hZac1, c-Fos, p21 and GAPDH (internal control) in HeLa cells transfected with either siRNA against hZac1 (shZac1) or control
siRNA (shLacZ) for the indicated time. Band intensities were evaluated with ImageJ version 1.44a (NIH, USA). All target genes from shLacZ for 48 h were set to 100 to compare the
effects from the shZac1 samples.
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c-Fos, with and without PMA treatment
Considering the observed physical interaction between either c-
Jun or c-Fos and mZac1, which enhanced PMA-induced AP-1 activity
(Figs. 1–4), we further examined whether mZac1 could modulate the
inherent transactivation abilities of c-Jun and c-Fos individually.
Fragments of c-Jun and c-Fos were fused to Gal4 DBD and tested for an
effect of mZac1 on their activation of a Gal4-responsive reporter gene
in transiently transfected HeLa cells. Without mZac1, the maximum
reporter activities were observed with c-Fos212–380 (42-fold) and c-
Jun1–122 (17-fold) (Fig. 5A, compare histograms 2–5 for c-Fos and 6–
10 for c-Jun, closed columns). All transactivation activities of c-Jun
and c-Fos fragments were enhanced when HeLa cells were exposed to
PMA (Fig. 5B, compare closed columns). With PMA, the maximumactivities were observed with c-Fos212–380 (438-fold) and c-Jun1–122
(40-fold) (Fig. 5B). Co-transfected mZac1 under the aforementioned
conditions enhanced the transactivation activity of full-length c-Fos
but not c-Jun, with and without PMA (Fig. 5A and B, compare
histograms 1, 2, and 6, pb0.005 vs. pN0.05). However, mZac1
enhanced the transactivation activity of truncated c-Jun, such as c-
Jun1–122 and c-Jun1–267 (Fig. 5A and B, compare histograms 6–10). The
transactivation activities of various c-Fos fragments were not only
enhanced by co-transfected mZac1 but were also further enhanced by
additional PMA treatment. The maximum effect was observed on c-
Fos212–380, where mZac1 enhancement was 20-fold, PMAwas 10-fold,
and mZac1 and PMA together was 72-fold (Fig. 5A and B, compare
histograms 1–5, closed and open columns, pb0.005). In the western
blot analysis, these different levels of transactivation activity did not
correspond to Gal4-DBD-fused construct expression levels in the cells
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c-Fos proteins via GST pull-down analysis (Fig. 5D and E) and
determined that this interaction site was at amino acids 1–334 in c-
Jun and amino acids 1–101 in c-Fos. However, mZac1 might modulate
c-Fos C-terminal transactivation activities, at amino acids 102–380
and 212–380, via an indirect pathway (Fig. 5B, histograms 4 and 5,
and Fig. 5E).
3.5. mZac1-induced c-Fos promoter activity is suppressed by c-Fos and
c-Jun:c-Fos heterodimers
An AP-1 binding site adjacent to the SRE in the c-Fos promoter-
proximal region binds c-Jun:c-Fos heterodimers and CREB/ATF family
transcription factors through which negative auto-feedback of c-Fos
transcription might be mediated [36]. Using the luciferase reporter
assay, our data indicate that PMA acts synergistically with mZac1 for
c-Fos promoter activation (Fig. 6A, and compare histogram 1 in Fig. 6B,
pb0.005). c-Jun and c-Fos have additive effects on c-Fos promoter
activity in the absence of PMA and mZac1 (Fig. 6B, compare
histograms 1–4, closed columns, top panel). mZac1-induced c-Fos
promoter activity could be enhanced by c-Jun, but c-Fos and c-Jun:c-
Fos heterodimers suppressed the activity in the absence of PMA
treatment (Fig. 6B, compare histograms 1–4, top panel, pb0.005).
However, when HeLa cells were exposed to PMA alone, c-Jun and c-
Jun:c-Fos heterodimers had little or no effect on PMA-induced c-Fos
promoter activity, but c-Fos suppressed this PMA-induced promoter
activity (Fig. 6B, compare histograms 1–4, closed columns, bottom
panel). Although mZac1 and PMA act synergistically on c-Fos
promoter activity, repression of this promoter from either c-Fos
alone or the c-Jun:c-Fos heterodimer could not be alleviated (Fig. 6B,
compare histograms 1–4, open columns, bottom panel, pb0.05),supporting a c-Fos transcription negative auto-feedback. We tested
endogenous c-Fos expression levels in the presence and absence of
overexpressed mZac1 and/or PMA treatment. In addition to inducing
c-Fos phosphorylation, similar to the PMA treatment (Fig. 1C), mZac1
induced less extensive endogenous c-Fos expression than PMA and
the positive control, Ras(V12). Interestingly, overexpressed mZac1
did not further enhance PMA-induced endogenous c-Fos protein
expression (Fig. 6C, compare lanes 1–5).
3.6. mZac1-induced p21 expression is enhanced by c-Jun:c-Fos
heterodimers but not c-Jun or c-Fos alone
p21 levels are affected by diverse signaling stimuli, including
phorbol esters [37,38]. As mZac1 also directly interacts with p53, we
used HeLa and HeLa/p53 shRNA cells to examine the functional
relationship betweenmZac1, p53 or/and PMA on p21 gene expression
(Fig. 7). In both HeLa and HeLa/p53 shRNA cells, mZac1 enhanced the
effect of PMA on p21 promoter induction (Fig. 7A), and either the
reporter activity or the induction-fold via mZac1 was higher in HeLa
than HeLa/p53 shRNA cells. Maximum induction of p21 protein
expression was observed after 6 h of PMA treatment in HeLa and
HeLa/p53 shRNA cells using western blot analysis, although p21
protein expression levels were lower in HeLa/p53 shRNA cells than
parental HeLa cells (Fig. 7B). We also observed a decrease in
endogenous p53 proteins for PMA-treated cells.
c-Jun functions as a direct repressor of p53 gene transcription and
decreases the transcriptional activity of p53 itself by down-regulating
its ability to activate the p21 gene [3,38,39]. Here, we examined the
functional interaction between mZac1, c-Jun, and/or PMA in p21 gene
and protein regulation in HeLa and HeLa/shp53 cells. We found that c-
Jun reduced mZac1-induced p21 protein expression absent from PMA
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in PMA-treated HeLa cells, as PMA treatment decreased endogenous
p53 (Fig. 7C and D, compare lanes 2 and 4 or 6 and 8). In addition, weconstructed tet-on inducible HeLa/TR/mZac1 cells to demonstrate
that the induction of p21 protein via tet-on mZac1 arrested the cell
cycle in G1 phase (Fig. 7E and F).
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presence of 0.25 μg of either empty vector (closed columns) or pSG5.HA.mZac1 (open columns). The cells transfected as in (A) were treated with 162 nM PMA for 16 h (B, bottom
panel). The numbers above the columns indicate the luciferase activity relative to an index of 1 for samples to which no factor was added. These data (A and B) are the average of
three experiments (mean±S.D.; n=3). (C) The HeLa cells were transiently transfected with 1 μg of either empty vector (lane 1), Zac1 (lane 3), or control plasmid DNA [Ras(V12),
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H2A.X protein phosphorylation
PMA is a well-known PKC activator, which has important functions
in regulating the cell cycle and intracellular signal transduction
[5,24,40]. Hence, we examined the cell cycle proﬁle of PMA-treated
HeLa cells with and without exogenous mZac1 overexpression
(Fig. 8A and B). A representative analysis of HeLa cells treated with
PMA for 24 h is shown in Fig. 8, and it suggests that mZac1 plays a role
in sub-G1 phase induction. Except for the 6-hour PMA treatment, PMA
treatment increased the percentage of sub-G1 and G1 phase but
decreased the percentage of S phase (Fig. 8B, open). mZac1
transfection dramatically increased the percentage of sub-G1 phase
but inverted the PMA-induced G2/M phase (Fig. 8B, closed).
The data shown in Fig. 7C suggest that PMA signiﬁcantly induced
expression of the p21 protein, which is involved in G1/S phase
progression. Comparing the time-course of p21 protein induction and
cell cycle progression, we speculate that other undeﬁned factors are
also involved in the PMA treatment response. Hence, we examined
the phosphorylation status of histone 3 (serine residue 10) and H2A.X
(serine residue 139). p21 induction after a 6-h treatment was
inconsistent with p53 protein levels, suggesting p53-independence.
After PMA treatment of HeLa cells, we observed transient increases in
H3 (phosphorylated S10) and γ-H2A.X between 12–16 h and after
9 h, respectively (Fig. 8C, left panel). Overexpressed mZac1 primarilyenhanced the time-course for p21 induction and induction of H3
(phosphorylated S10) as well as prolonged γ-H2A.X induction in HeLa
cells (Fig. 8C, right panel). These mZac1-induced protein differences
in γ-H2A.X might be involved in the increased percentage of sub-G1
phase when HeLa cells are treated with PMA.
4. Discussion
Zac1 was initially identiﬁed with p53 in a functional screening
system via their common ability to induce PACAP-1-R expression [8].
PACAP-1-R binding peptides stimulate the transcription of responsive
genes via AP-1- and CREB-dependent pathways, but the detailed
mechanisms are poorly understood. In this study, the results from
mZac1 physically and functionally interacting with selective AP-1
proteins, such as c-Jun and c-Fos, link the roles of PACAP-1-R and
mZac1 in AP-1 activation. In Fig. 1, our observation suggests that
mZac1 can enhance and prolong PMA-responsive AP-1 activity in
HeLa cells, and this effect is independent of p53 and HPV oncopro-
teins, as mZac1 exhibits the same ability in both HeLa/p53 shRNA and
C33A cells (data not shown).
A role for AP-1 in the control of cellular homeostasis has been
suggested, as mitogenic stimulation can induce AP-1 activity, and
various Fos and Jun proteins are expressed differently during cell cycle
progression [4]. Our current data suggests that the functional
interactions between mZac1 and either c-Jun, c-Fos, or c-Jun:c-Fos
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2058 W.-M. Wang et al. / Biochimica et Biophysica Acta 1813 (2011) 2050–2060heterodimers in HeLa cells vary depending on the promoter context,
such as the collagenase, 7xAP-1, c-Fos and p21 promoters. Hence, the
effect on PMA-induced mZac1 activation of AP-1 may involve
combinatorial AP-1 subunits and additional factors that interact
with mZac1 in the cells.
Several AP-1 proteins (c-Fos, FosB and c-Jun) exhibit transforming
potential, which correlates with their transcriptional activation and
DNA-binding activities [3]. Our results suggest that mZac1 might be
involved in AP-1 function by enhancing c-Jun and c-Fos transactiva-
tion activities, which affect AP-1 transcriptional activation, and that itmight heterodimerize with either c-Jun or c-Fos to form various
functional AP-1 complexes. It is well known that the regulation of AP-
1 activity is complicated and occurs at different levels, including dimer
composition, transcriptional and post-translational events, as well as
ancillary protein interactions [5,6]. We suggest that mZac1 regulates
AP-1 activity via physical interactions with c-Jun and c-Fos,
enhancement of c-Jun and c-Fos transactivation, and induction of c-
Fos protein expression.
c-Jun is a direct repressor of p53 gene transcription and decreases
p53 transcription activity to down-regulate p21 gene activation [3,39].
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2059W.-M. Wang et al. / Biochimica et Biophysica Acta 1813 (2011) 2050–2060In contrast, mZac1 is a direct coactivator of p53 gene transcription and
increases p53 transcriptional activity; for example, mZac1 and p53
both synergistically activate p21 gene and protein expression [20].
mZac1 enhancement of the p21 promoter might be mediated via both
the p53 and PMA-responsive elements in HeLa cells. PMA induced
endogenous p21 protein levels in HeLa/p53 shRNA cells (Fig. 7D, lanes5–8), suggesting that there is a p53-indpendent p21 protein induction
pathway in HeLa cells [17]. Repression of mZac1-induced p21 protein
expression by c-Jun was also restored by PMA. Thus, PMA induction of
p21 protein might be not only enhanced by increased p21 mRNA
stability [40] but also mediated via unidentiﬁed trans-factors other
than p53 in HeLa cells [38].
2060 W.-M. Wang et al. / Biochimica et Biophysica Acta 1813 (2011) 2050–2060Zac1, similar to p53, is a gene product able to concomitantly induce
both programmed cell death and cell cycle arrest in vitro[8,11]. AP-1
and p21 are likely both involved in themodulation of cell proliferation
and apoptosis via speciﬁc mechanisms [37,41,42]. In light of its dual
role, determination of cell viability and elimination of damaged cells
may be ‘ﬁne-tuned’ by Zac1 to control PACAP-1-R, c-Jun, c-Fos, p53
and p21 transactivation. Hence, our work provides new insights into
the mechanism of Zac1 regulation of AP-1 activity that induces cell
cycle arrest and apoptosis in vivo.
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